TNF and systemic-onset juvenile idiopathic arthritis: <b>Background:</b> Tumor necrosis factor-α (TNFα) inhibitors have significantly improved outcomes in children with non-systemic juvenile idiopathic arthritis (JIA), achieving long-term clinical remission for many patients.